This refresh
Data-driven refresh August 20, 2026. The Top Picks are the Bull Rankings quality-growth screen — strong, growing businesses with durable returns at a fair price (PEG / EV-EBIT vs sector, ROIC, free cash flow). Scanned every US-listed common stock on NYSE, NASDAQ, NYSE American, and NYSE Arca (5,245 tickers); 1,668 scored on the quality-growth model (financials route to a separate card). Fundamentals from Yahoo Finance quoteSummary reconciled with as-reported SEC EDGAR filings; narrative authored by Groq (with Gemini and data-driven fallbacks).
Top Picks — quality compounders at a fair price
1. ADBE — Adobe Inc. · score 89.4
Software - Application · price $272.22 · 1Y $270.61 · 5Y $396.19 · 10Y $587.73
FCF $10.3b A- · Rev +11.5% B · D/E 0.61 C+ · P/E 15.6x A- · PEG 0.66 A-
Why now. Adobe’s Digital Media subscription engine is the growth engine, delivering 11.5% YoY revenue growth, a rock‑solid 28.7% profit margin and $10.3B of free cash flow that fuels both buybacks and R&D. With a P/E of 15.6x and ROE of 62.8%, the company compounds earnings at a rate that outpaces peers, making the next 12‑months a clear upside play.
Moat. The subscription‑based Creative Cloud and Experience Cloud lock in photographers, video editors, marketers and enterprises on a multi‑year platform, creating high switching costs. Adobe’s 62.8% ROE stems from pricing power in a category‑leader that can monetize new AI‑driven features without eroding margins, a moat competitors can’t replicate quickly.
Risk. A high beta of 1.4 makes Adobe vulnerable to market swings, and a debt‑to‑equity of 0.61 adds leverage risk if growth stalls. The reverse‑DCF shows the stock pricing in only ~1% annual FCF growth—far below the 11.5% revenue expansion, suggesting the market is already pricing in a slowdown; a missed earnings beat or a slowdown in subscription renewals would trigger a sell‑off.
Horizon. 1-3 yr $270.61 (analyst consensus (n=34)) — fundamentals + valuation re-rating. 5 yr $396.19 at ~8% CAGR — compounding case rests on the competitive position widening. 10 yr $587.73 if current growth sustains into durable earnings power.
2. HRMY — Harmony Biosciences Holdings, Inc. · score 88.7
Biotechnology · price $38.07 · 1Y $46.10 · 5Y $67.50 · 10Y $100.12
FCF $355m C · Rev +24.3% A- · D/E 0.16 B+ · P/E 12.3x A · PEG 0.44 A
Why now. Harmony Biosciences is a compelling growth story trading at a deep discount, driven by the continued expansion of its flagship WAKIX franchise and pipeline potential in rare neurological diseases. Our model's strongest pillar, Value (95/100), highlights this disconnect: a robust 24.3% FY YoY revenue growth and a healthy 18.9% profit margin are priced at a mere 12.3x TTM P/E. The market is dramatically underestimating the long-term earnings power from WAKIX and future indications like Prader-Willi Syndrome, creating a significant opportunity for patient investors.
Moat. Harmony's durable edge stems from WAKIX (pitolisant), a molecule with a novel mechanism of action specifically approved for excessive daytime sleepiness in narcolepsy, providing a differentiated therapeutic option in a rare disease market. The company's focus on developing and commercializing therapies for rare neurological diseases, coupled with its ongoing Phase 3 and Phase 2 clinical trials for Pitolisant in indications like Prader-Willi Syndrome and Myotonic Dystrophy, establishes a pipeline of specialized intellectual property and market expertise that is difficult for competitors to quickly replicate.
Risk. The bear case hinges on Harmony's reliance on WAKIX and the execution risk inherent in expanding its pipeline, a concern reflected in our model's weakest pillar, Quality (80/100). Despite strong current revenue growth, the market's skepticism is evident in the reverse DCF, which implies a sustained ~-18%/year free-cash-flow growth for 10 years to justify today's price, suggesting significant doubt about future product success or WAKIX's longevity. A sustained deceleration in WAKIX sales growth or clinical trial setbacks for Pitolisant in Prader-Willi Syndrome or Myotonic Dystrophy would confirm this pessimistic outlook and erode investor confidence.
Horizon. 1-3 yr $46.10 (analyst consensus (n=10)) — fundamentals + valuation re-rating. 5 yr $67.50 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $100.12 if current growth sustains into durable earnings power.
3. DLO — DLocal Limited · score 88.6
Software - Infrastructure · price $14.34 · 1Y $18.40 · 5Y $26.94 · 10Y $39.96
FCF $413m C · Rev +46.6% A · D/E 0.12 B+ · P/E 21.1x B+ · PEG 0.67 A-
Why now. DLocal’s cross‑border payment platform for high‑velocity merchants such as ride‑hailing and streaming is exploding, delivering 46.6% YoY revenue growth, 18% profit margin and a staggering 34.6% ROE while generating $413 m of free cash flow. Those fundamentals sit under a market‑price that implies a reverse‑DCF free‑cash‑flow growth of –8%/yr, meaning the market is already pricing in far more optimism than the business can sustain, leaving a clear upside to the consensus 1‑yr target of $18.40. The thesis rests on the relentless compounding of merchant‑on‑boardings in the global payments wave.
Moat. The moat comes from DLocal’s integrated pay‑in/pay‑out suite that connects merchants to hundreds of local cards, bank transfers and alternative payment methods, creating a high‑switching‑cost ecosystem. This breadth lets DLocal charge premium pricing, driving the 34.6% ROE, and the platform lock‑in for large SaaS and streaming customers makes it hard for rivals to replicate the network quickly.
Risk. The biggest risk is dilution: our model flags shareholder dilution that could erode per‑share earnings even as the business scales, and the current P/E of 21.1× already reflects lofty growth expectations that may falter if the 46.6% revenue surge slows. A missed earnings beat or a significant increase in share count would confirm the bear case and invalidate the growth narrative.
Horizon. 1-3 yr $18.40 (analyst consensus (n=10)) — fundamentals + valuation re-rating. 5 yr $26.94 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $39.96 if current growth sustains into durable earnings power.
4. NBIX — Neurocrine Biosciences, Inc. · score 88
Drug Manufacturers - Specialty & Generic · price $152.93 · 1Y $211.57 · 5Y $309.76 · 10Y $459.51
FCF $870m C+ · Rev +34.4% A · D/E 0.12 B+ · P/E 22.4x B+ · PEG 0.46 A
Why now. NBIX’s growth engine is anchored by INGREZZA, the only FDA‑approved therapy for tardive dyskinesia, which is expanding rapidly as the aging psychiatric population swells; the drug now drives 20.9% profit margin and fuels a 34.4% YoY revenue surge. Coupled with a market‑cap of $15.5B and a low beta of 0.39, the business compounds earnings at a pace the market already rewards, making the 8% free‑cash‑flow growth baked into today’s price a modest assumption. The thesis rests on continued uptake of INGREZZA and pipeline progress in movement‑disorder candidates.
Moat. INGREZZA’s unique mechanism and orphan‑drug status create high switching costs for neurologists and psychiatrists, locking in a premium pricing regime that underpins the 19.1% ROE. The company’s focused specialty‑drug portfolio, combined with a disciplined 0.12 debt‑to‑equity balance, lets it reinvest cash without diluting shareholders, preserving the economic moat around its high‑margin franchise.
Risk. The bear case hinges on the concentration risk of INGREZZA; any adverse safety signal or competitive entrant could compress the 22.4 P/E multiple, which is already elevated for a specialty biotech. A slowdown in revenue growth below the current 34.4% YoY would also erode the free‑cash‑flow growth assumption, and a breach of the low‑debt cushion would trigger a sell‑off. A missed regulatory milestone on the NBI‑1076986 candidate would confirm the downside.
Horizon. 1-3 yr $211.57 (analyst consensus (n=27)) — fundamentals + valuation re-rating. 5 yr $309.76 at ~15% CAGR — compounding case rests on the competitive position widening. 10 yr $459.51 if current growth sustains into durable earnings power.
5. PGY — Pagaya Technologies Ltd. · score 86.2
Software - Infrastructure · price $20.24 · 1Y $29.20 · 5Y $42.75 · 10Y $63.42
FCF $252m C · Rev +25.6% A- · D/E 1.34 C · P/E 14.4x A- · PEG 0.04 A
Why now. Pagaya Technologies is a deeply undervalued growth engine, with its proprietary AI-powered technology, particularly the Decline Monetization product, driving significant partner expansion by approving customers financial services would otherwise decline. Our model's Value pillar score of 99, its strongest pillar, unequivocally signals deep undervaluation, reinforced by an exceptional PEG ratio of 0.04 and robust 25.6% FY YoY revenue growth. The market is dramatically underpricing Pagaya's ability to compound its AI-driven network effects, as today's price implies an unsustainable ~-15%/yr free-cash-flow growth sustained for 10 years, a stark contrast to its actual revenue trajectory.
Moat. Pagaya's durable edge stems from its proprietary artificial intelligence-powered technology and data science, which underpins its core offerings like Decline Monetization and First Look. This technology creates a powerful network effect: as more financial services partners utilize Pagaya's platform, the AI models become increasingly sophisticated and accurate, enhancing the value proposition and making it difficult for competitors to match the breadth and depth of its data-driven insights. This continuous feedback loop reinforces its competitive position in assessing loan applications, driving a strong ROE of 19.5%.
Risk. Skeptics would point to Pagaya's extreme market sensitivity, evidenced by a Beta of 5.37, indicating that any market downturn could disproportionately impact the stock. Our model's "Diluting shareholders" caution signal, coupled with a Quality score of only 70 (our weakest pillar), suggests potential concerns regarding capital structure and underlying business quality. A sustained period of economic contraction impacting consumer loan demand, alongside continued equity dilution and a failure to expand its financial services partner network, would confirm the bear thesis.
Horizon. 1-3 yr $29.20 (analyst consensus (n=10)) — fundamentals + valuation re-rating. 5 yr $42.75 at ~16% CAGR — compounding case rests on the competitive position widening. 10 yr $63.42 if current growth sustains into durable earnings power.
6. NVDA — NVIDIA Corporation · score 85.9
Semiconductors · price $216.85 · 1Y $304.12 · 5Y $445.26 · 10Y $660.52
FCF $119.1b A · Rev +70.7% A · D/E 0.07 B+ · P/E 33.2x B · PEG 0.60 A-
Why now. NVIDIA’s AI‑driven Compute & Networking platform is cementing its role as the de‑facto engine for data‑center scale inference, and that engine is exploding – revenue is up 70.7% YoY, free cash flow tops $119.1 B, and profit margins sit at a staggering 63%. Our Bull Rankings model gives NVDA an 85.9/100 quality‑growth score, with Growth as the strongest pillar, confirming that the compounding engine is real and durable. The thesis rests on the fact that the market’s 50% /yr reverse‑DCF FCF growth assumption is already below the current revenue acceleration, leaving upside if the AI spend tailwinds persist.
Moat. NVDA’s moat lives in its Compute & Networking segment, where its accelerated‑computing GPUs and networking fabrics are embedded in hyperscale cloud providers and enterprise AI clusters – a switch‑cost nightmare for customers that have built software stacks around CUDA. The 81.7% ROE reflects pricing power from being the category leader in AI‑centric silicon, allowing the company to capture premium spreads that rivals cannot match without massive R&D spend.
Risk. The stock trades at a lofty 33.2× forward P/E and a beta of 2.21, meaning any slowdown in AI spend or a miss on the 70.7% revenue growth trajectory would slam the valuation. Our model flags Value as the weakest pillar, underscoring that the price already assumes aggressive 50% /yr FCF growth; a single quarter of margin compression or a shift to cheaper alternatives would validate the bear case. A sustained dip in profit margin below 60% would be the concrete trigger that breaks the bull thesis.
Horizon. 1-3 yr $304.12 (analyst consensus (n=58)) — fundamentals + valuation re-rating. 5 yr $445.26 at ~15% CAGR — compounding case rests on the competitive position widening. 10 yr $660.52 if current growth sustains into durable earnings power.
7. GDDY — GoDaddy Inc. · score 85.4
Software - Infrastructure · price $98.19 · 1Y $104.80 · 5Y $153.44 · 10Y $227.61
FCF $1.7b C+ · Rev +7.4% B · D/E n/a · P/E 14.6x A- · PEG 0.68 A-
Why now. GoDaddy’s Applications & Commerce segment, anchored by the high‑engagement Websites + Marketing suite, is delivering 7.4% YoY revenue growth and a robust 17.8% profit margin, while the balance sheet is generating $1.7 B of free cash flow. Our Bull Rankings model awards the stock an 85.4/100 quality‑growth score—its strongest pillar, Quality (95), reflects the durable cash‑generating engine of its platform, and even with a weaker Growth pillar (75) the business still compounds earnings. The market already prices in a steep -15% annual FCF decline (reverse DCF), a pessimistic view that is out of step with the actual growth trajectory, making the current price a bargain that rests on the continued expansion of the A&C suite.
Moat. The integrated Websites + Marketing and Managed WordPress tools lock customers into a single ecosystem for site building, SEO, and e‑commerce, creating high switching costs and recurring subscription revenue that competitors can’t replicate quickly without a comparable platform stack.
Risk. The growth pillar of our model is the weakest, and the modest 7.4% revenue acceleration may falter if larger SaaS players erode market share, compressing margins below the current 17.8% and forcing price pressure. A widening analyst target range of $80–$170 signals uncertainty; a sustained slowdown would validate the reverse‑DCF implied -15% FCF trajectory and drive the stock toward the lower end of that range.
Horizon. 1-3 yr $104.80 (analyst consensus (n=15)) — fundamentals + valuation re-rating. 5 yr $153.44 at ~9% CAGR — compounding case rests on the competitive position widening. 10 yr $227.61 if current growth sustains into durable earnings power.
8. INTU — Intuit Inc. · score 85
Software - Application · price $361.87 · 1Y $446.02 · 5Y $653.02 · 10Y $968.70
FCF $7.8b B+ · Rev +15.1% B+ · D/E 0.33 B · P/E 22.1x B+ · PEG 0.94 B+
Why now. Intuit Inc. is a compelling growth story trading at a deep discount, with our model's strongest pillar, Growth (90/100), clearly evident in its 15.1% FY YoY revenue growth. The market is dramatically underestimating its compounding power: today's price implies a ~-1%/yr free-cash-flow growth sustained for 10 years, a stark contrast to its actual $7.8b TTM FCF and a P/E of just 22.1. This disconnect presents a rare opportunity for patient investors to capitalize on the continued expansion of its Global Business Solutions segment, particularly through QuickBooks services and Mailchimp.
Moat. Intuit's durable edge stems from its deeply embedded ecosystem of financial management, payments, and marketing solutions for small and mid-market businesses, creating significant switching costs. Products like QuickBooks services and Mailchimp become mission-critical infrastructure, making it costly and disruptive for customers to migrate. This category leadership and sticky customer base drive its exceptional 22.2% Return on Equity, reflecting strong pricing power and efficient capital allocation.
Risk. The primary risk for Intuit lies in its valuation relative to sector peers, reflected in our model's weakest pillar, Value (80/100), despite a seemingly reasonable P/E of 22.1. Intense competition in the financial management and marketing automation space, particularly within the Global Business Solutions segment, could pressure margins or slow the impressive 15.1% revenue growth. A sustained deceleration in customer acquisition or average revenue per user for QuickBooks or Mailchimp would confirm the bear case, eroding the company's growth premium.
Horizon. 1-3 yr $446.02 (analyst consensus (n=33)) — fundamentals + valuation re-rating. 5 yr $653.02 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $968.70 if current growth sustains into durable earnings power.
9. DOCS — Doximity, Inc. · score 84.1
Health Information Services · price $25.94 · 1Y $29.39 · 5Y $43.03 · 10Y $63.83
FCF $306m C · Rev +11.2% B · D/E 0.01 A- · P/E 30.9x B · PEG 0.59 A-
Why now. DOCS’s AI‑powered workflow tool Ask is turning the platform into an indispensable clinical assistant, locking in physician usage and driving revenue that’s still expanding 11.2% YoY. The business converts that stickiness into a 25.5% profit margin and a healthy 18.2% ROE, while the Bull Rankings model awards a Quality‑growth score of 84.1 – its strongest pillar, Quality, confirming the durable competitive edge. Because the reverse‑DCF implies only ~8% free‑cash‑flow growth versus the actual 11.2% revenue growth, the market is already pricing in optimism, leaving upside for a disciplined buyer.
Moat. The Doximity platform’s network effect – every physician adds peers, content, and AI queries – creates a switching cost that rivals can’t replicate quickly, especially with HIPAA‑compliant Ask and Scribe embedded in daily workflows. This high‑engagement ecosystem fuels the 18.2% ROE, reflecting pricing power from being the go‑to digital hub for U.S. clinicians.
Risk. At a forward P/E of 30.9 and a beta of 1.21, the stock trades at a premium that could crumble if physician ad spend slows or if growth eases below the 11.2% pace, eroding the 25.5% margin cushion. A breach of the 52‑week low of $17.15 would signal that the market’s optimism is overstated and could trigger a sell‑off.
Horizon. 1-3 yr $29.39 (analyst consensus (n=18)) — fundamentals + valuation re-rating. 5 yr $43.03 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $63.83 if current growth sustains into durable earnings power.
10. CARG — CarGurus, Inc. Class A Common Stock · score 83.4
Auto & Truck Dealerships · price $36.89 · 1Y $41.50 · 5Y $60.76 · 10Y $90.13
FCF $315m C · Rev +13.9% B+ · D/E 0.70 B+ · P/E 19.0x B · PEG 1.08 B+
Why now. CARG is compounding cash: 18.2% profit margins and $315M in trailing free cash flow anchor a business that turns shopper traffic into dealer subscriptions and manufacturer ads without inventory risk. Digital Deal and Dealership Mode lock in dealer spend while shoppers self-qualify, driving 13.9% revenue growth even as unit auto sales soften. The crux: every incremental dollar of FCF is being returned to shareholders via buybacks, shrinking share count into a growing earnings base.
Moat. The moat is the flywheel between shoppers and dealers: CarGurus’ audience of car shoppers is the largest in the U.S. auto market, and dealers pay recurring subscription fees for access to these high-intent buyers. Dealership Mode embeds the platform into the physical dealership visit, creating a switching cost that competitors can’t replicate overnight. Our model’s Quality score of 88 reflects this pricing power from category leadership in online automotive marketplaces, where ROE of 66.6% is sustained by near-zero marginal cost to serve each additional shopper.
Risk. The stock is pricing in perfection: a P/E of 19x on 13.9% growth implies the bull case is already in the price, and our reverse DCF shows the market is assuming -2%/yr FCF growth for a decade. If Digital Deal adoption stalls or dealer churn ticks up, the high-margin subscription model cracks, and the stock will reprice to a lower multiple. The bear case is confirmed the day dealer subscription growth falls below 8% or the company pauses buybacks.
Horizon. 1-3 yr $41.50 (analyst consensus (n=12)) — fundamentals + valuation re-rating. 5 yr $60.76 at ~10% CAGR — compounding case rests on the competitive position widening. 10 yr $90.13 if current growth sustains into durable earnings power.
11. APP — AppLovin Corporation · score 83.3
Advertising Agencies · price $308.77 · 1Y $528.32 · 5Y $773.52 · 10Y $1,147
FCF $4.5b B · Rev +60.6% A · D/E 1.11 C+ · P/E 23.7x C+ · PEG 0.88 B+
Why now. The bull case hinges on MAX, AppLovin’s AI‑driven in‑app bidding platform, which is unlocking unprecedented inventory value for publishers and fueling a revenue surge of 60.6% YoY. That growth translates into a staggering 64.6% profit margin and a free‑cash‑flow stream of $4.5B, underpinning a sustainable compounding engine. With our model’s Growth pillar at 96, the thesis rests on MAX’s ability to keep the 10‑year implied FCF growth of ~14% realistic versus today’s 60% revenue expansion.
Moat. MAX creates a network effect: each additional publisher raises auction competition, locking in developers who rely on the platform’s real‑time optimization. This switching cost is reinforced by Adjust’s measurement suite, giving AppLovin a data moat that rivals can’t replicate quickly, and drives the high 64.6% margin that fuels free cash flow.
Risk. The bear case focuses on the lofty valuation – a P/E of 23.7 for a company with a beta of 2.53 signals market optimism that may be overstated, especially if revenue growth decelerates from the current 60.6% pace. A debt‑to‑equity of 1.11 adds leverage risk, and any slowdown in MAX adoption would crush the growth narrative. A sustained drop in margin or a rise in debt would confirm the downside.
Horizon. 1-3 yr $528.32 (analyst consensus (n=31)) — fundamentals + valuation re-rating. 5 yr $773.52 at ~20% CAGR — compounding case rests on the competitive position widening. 10 yr $1,147 if current growth sustains into durable earnings power.
12. EPAM — EPAM Systems, Inc. · score 82
Information Technology Services · price $106.76 · 1Y $122.82 · 5Y $179.83 · 10Y $266.76
FCF $483m C · Rev +10.8% B · D/E 0.04 A- · P/E 14.5x A- · PEG 0.57 A-
Why now. EPAM’s digital platform engineering franchise is exploding, driven by its cloud‑services and AI‑enabled data analytics practice that now commands $483 m of free cash flow and a 10.8% YoY revenue growth rate, while trading at a modest PE of 14.5x and a sub‑1.0 PEG of 0.57. The combination of a low‑debt balance sheet (DE 0.04) and a buy‑back signal from our model means the market is undervaluing a high‑margin growth engine, setting the stage for a multi‑year earnings compounding rally. The thesis rests on the continued secular shift to cloud and AI, which will keep EPAM’s engineering spend expanding at double‑digit rates.
Moat. EPAM locks in enterprise clients through end‑to‑end platform engineering engagements that embed its proprietary integration frameworks and smart‑automation tools, creating high switching costs for large IT spenders. Its ability to deliver cross‑platform migration and customized cloud roadmaps gives it pricing power, reflected in an ROE of 11.4% that outpaces many pure‑play services peers. This depth of technical integration makes it difficult for pure‑play consultancies to replicate EPAM’s bundled offering quickly.
Risk. The biggest headwind is the premium valuation implied by the reverse‑DCF, which assumes a sustained 3% annual free‑cash‑flow growth for a decade—far below the actual 10.8% revenue growth, suggesting the market is already pricing in aggressive optimism. A slowdown in cloud spend or a macro‑driven IT budget cut could compress margins and push the PE above the sector average, validating the bear view. A breach of the 52‑week low ($73.06) would trigger stop‑losses and confirm the over‑optimism narrative.
Horizon. 1-3 yr $122.82 (analyst consensus (n=17)) — fundamentals + valuation re-rating. 5 yr $179.83 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $266.76 if current growth sustains into durable earnings power.
13. LRN — Stride, Inc. · score 81.9
Education & Training Services · price $84.07 · 1Y $96.68 · 5Y $141.55 · 10Y $209.98
FCF $433m C · Rev +4.7% C+ · D/E 0.33 A- · P/E 11.8x A · PEG 0.49 A
Why now. Stride, Inc. presents a compelling value opportunity within the education technology sector, trading at a mere 11.8x TTM P/E and an exceptional 0.49x PEG ratio. Our Bull Rankings model assigns a Quality-Growth score of 81.9/100, with Value as its strongest pillar at 95, underscoring the market's deep undervaluation of its robust free cash flow of $433m. The market is pricing in a ~-11%/yr free-cash-flow decline over the next decade, a stark disconnect from its current 4.7% revenue growth and consistent profitability, suggesting significant upside as the market recognizes the durability of its educational platform and specialized curriculum in software engineering and healthcare.
Moat. Stride's durable edge stems from its comprehensive, end-to-end educational platform, which integrates content management, learning management, student information, and data analytics into a single sign-on system. This deep integration creates significant switching costs for educational institutions and students, making it difficult for competitors to dislodge. The company's impressive 20.7% Return on Equity reflects the pricing power derived from this proprietary platform and its specialized curriculum in high-demand fields like software engineering and healthcare, ensuring sustained profitability.
Risk. The primary bear case against Stride centers on its decelerating growth trajectory, with revenue growth at a modest 4.7% FY YoY, which our model identifies as its weakest pillar (Growth 67). Despite its platform's stickiness, the online education market is increasingly competitive, and Stride's reliance on its proprietary curriculum and content in specific fields like software engineering and healthcare could face pressure from new entrants or evolving educational demands. A sustained decline in free cash flow, indicated by the market's current ~-11%/yr implied FCF growth, would confirm that Stride's ability to expand its user base and monetize its platform is fundamentally challenged.
Horizon. 1-3 yr $96.68 (structural (no analyst coverage)) — fundamentals + valuation re-rating. 5 yr $141.55 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $209.98 if current growth sustains into durable earnings power.
14. EXLS — ExlService Holdings, Inc. · score 81.8
Information Technology Services · price $37.05 · 1Y $44.38 · 5Y $64.97 · 10Y $96.38
FCF $297m C · Rev +13.4% B+ · D/E 0.57 C+ · P/E 23.4x B+ · PEG 1.10 B+
Why now. EXLS is poised to dominate AI‑driven claims and underwriting automation for insurers, a segment that now fuels 13.4% YoY revenue growth and underpins its 11.7% profit margin. The business converts that margin into a robust ROE of 32.3% while returning cash via buybacks, meaning each dollar of earnings compounds at a rate far above peers. The thesis rests on the relentless expansion of data‑intensive insurance services that lock in high‑margin contracts and generate sustainable free cash flow.
Moat. The company’s moat lives in its end‑to‑end AI platform for claims management and policy servicing, which embeds deep data sets and actuarial models that insurers cannot replace without costly re‑engineering. This creates high switching costs and allows EXLS to command pricing power, evident in its 32.3% ROE, far above the sector average.
Risk. The bear case centers on the elevated PE of 23.4x and a PEG of 1.1, implying the market already prices in near‑term growth that may be hard to sustain if insurance spend cycles dip; a slowdown in the insurance sector would compress margins and pressure the 0.57 debt‑to‑equity ratio. A breach of the 52‑week low ($24.85) would signal that growth expectations were overblown and could trigger share‑price erosion.
Horizon. 1-3 yr $44.38 (analyst consensus (n=8)) — fundamentals + valuation re-rating. 5 yr $64.97 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $96.38 if current growth sustains into durable earnings power.
15. FISV — Fiserv, Inc. · score 81.4
Sector n/a · price $51.38 · 1Y $62.18 · 5Y $91.04 · 10Y $135.05
FCF $3.9b B · Rev +9.3% B · D/E n/a · P/E 9.8x A- · PEG 0.78 A-
Why now. The Bull Rankings model gives FISV an 81.4/100 quality‑growth score, with Value as its strongest pillar, meaning the market is already rewarding its cash‑generating engine. The business’s 9.3% YoY revenue growth and 17.3% profit margin are being turned into $3.9B of free cash flow, fueling aggressive buybacks that compress the share count and amplify earnings. The whole thesis hinges on the continuation of this cash‑flow compounding as the payments ecosystem expands.
Moat. FISV’s moat lies in its integrated payments‑processing platform that locks in large banks and merchants through deep API integration and data‑driven services, creating high switching costs and a network effect that competitors can’t replicate quickly. Its ROE of 10.4% reflects pricing power derived from being the default processor for thousands of mid‑size institutions, allowing it to capture incremental margin on every transaction.
Risk. The bear case centers on the reverse‑DCF signal: the current price embeds a -15% annual free‑cash‑flow growth rate for the next decade, far below the actual 9.3% revenue growth, implying that any slowdown or margin compression would make the valuation untenable. A miss on the next earnings beat that pushes the PE above 12× would confirm that the market’s optimism was misplaced and could trigger a sell‑off.
Horizon. 1-3 yr $62.18 (analyst consensus (n=28)) — fundamentals + valuation re-rating. 5 yr $91.04 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $135.05 if current growth sustains into durable earnings power.
16. ADMA — ADMA Biologics, Inc. · score 81.3
Biotechnology · price $9.76 · 1Y $17.00 · 5Y $24.89 · 10Y $36.92
FCF $116m C · Rev +8.0% B · D/E 1.11 C · P/E 13.9x A- · PEG 0.60 A-
Why now. ADMA’s market‑leading IVIG franchise—anchored by BIVIGAM and ASCENIV—drives a high‑margin, cash‑rich business that can compound earnings at double‑digit rates. The company posts a 33% profit margin, a stellar ROE of 41.4%, and a PE of 13.9x despite a market cap of only $2.2 B, underscoring the earnings power hidden in its specialty plasma‑derived products. With revenue still growing 8% YoY and a buy‑back program accelerating share‑count reduction, the compounding engine rests on the durable demand for immune‑globulin therapy.
Moat. ADMA controls the full plasma‑to‑product chain through its ADMA BioManufacturing and Collection Centers, creating a high barrier to entry and low‑cost supply of IVIG. This vertical integration yields pricing power in the primary humoral immunodeficiency market, reflected in a ROE above 40%, and the FDA‑approved biologics cannot be swapped for generic substitutes without extensive clinical validation, locking in hospitals and specialty pharmacies as long‑term customers.
Risk. The stock trades at a modest multiple, but the Bull Rankings model flags a growth weakness: revenue is only 8% YoY while the reverse‑DCF assumes just 4% annual free‑cash‑flow growth for the next decade, suggesting the market may already be pricing in limited upside. A debt‑to‑equity of 1.11 adds leverage risk if cash conversion falters, and any regulatory setback to BIVIGAM or ASCENIV would instantly erode the high‑margin franchise. A sustained slowdown in IVIG demand would confirm the bear case.
Horizon. 1-3 yr $17.00 (analyst consensus (n=5)) — fundamentals + valuation re-rating. 5 yr $24.89 at ~21% CAGR — compounding case rests on the competitive position widening. 10 yr $36.92 if current growth sustains into durable earnings power.
17. RMD — ResMed Inc. · score 81
Medical Instruments & Supplies · price $228.44 · 1Y $245.50 · 5Y $359.44 · 10Y $533.20
FCF $1.6b C+ · Rev +9.9% B · D/E 0.13 B+ · P/E 21.9x B+ · PEG 1.34 B
Why now. ResMed’s AirView cloud platform, paired with its portable diagnostic devices like ApneaLink Air and NightOwl, is locking hospitals, sleep clinics and home-care providers into a data-rich ecosystem that fuels recurring SaaS revenue. That ecosystem is expanding at a solid 9.9% YoY revenue growth, backed by a 26.9% profit margin and a 23.1% ROE, while management just announced a dividend increase, underscoring confidence in cash generation. The thesis hinges on the compounding power of cloud-connected sleep-health services that will keep margins high and cash flow growing.
Moat. The AirView platform creates a high-switching-cost moat: clinicians upload patient data daily, integrate treatment protocols, and rely on ResMed’s validated algorithms, making migration to rivals costly and disruptive. This lock-in, combined with ResMed’s pricing power in the sleep-apnea market, drives the 23.1% ROE and sustains its low 0.13 debt-to-equity balance sheet, enabling reinvestment without financial strain.
Risk. At a 21.9× P/E the stock trades well above the sector average, implying the market already expects a 5% annual free-cash-flow growth for the next decade—far below the 9.9% revenue growth we see today, suggesting any slowdown would quickly erode valuation. A modest dip in reimbursement rates or a successful competitor’s home-sleep-test offering could compress margins and trigger a re-rating. The bear case materializes if the implied growth proves unrealistic and the stock slides toward its 52-week low of $180.27.
Horizon. 1-3 yr $245.50 (analyst consensus (n=16)) — fundamentals + valuation re-rating. 5 yr $359.44 at ~9% CAGR — compounding case rests on the competitive position widening. 10 yr $533.20 if current growth sustains into durable earnings power.
18. PRDO — Perdoceo Education Corporation · score 80
Education & Training Services · price $32.48 · 1Y $37.35 · 5Y $54.69 · 10Y $81.12
FCF $221m C · Rev +11.7% B · D/E 0.11 A- · P/E 11.8x A · PEG 0.70 A-
Why now. The bull case hinges on Colorado Technical University’s (CTU) dominance in fast‑growing career‑oriented online fields—especially nursing and cybersecurity—fueling a revenue expansion of 11.7% YoY while the company converts that top‑line strength into a robust 20.6% profit margin and delivers $221 m of free cash flow. Our Bull Rankings model awards PRDO an 80/100 quality‑growth score, with Quality (89) as the strongest pillar, underscoring the durability of its earnings power, and the stock trades at a modest PE of 11.8 and PEG of 0.7, indicating cheap growth. The thesis rests on the continued compounding of high‑margin enrollment in CTU’s high‑demand programs.
Moat. PRDO’s moat derives from CTU’s specialized curriculum in scarce, high‑paying occupations—nursing, cybersecurity, health‑care management—paired with a blended‑learning delivery that locks in students through tuition‑based contracts and limited transferability, creating a sticky revenue base. The low debt‑to‑equity of 0.11 and a ROE of 17.1% reflect pricing power and efficient capital use in these niche segments, which competitors cannot replicate quickly without similar accreditation and online infrastructure.
Risk. The bear case centers on the Bull Rankings model’s reverse‑DCF implying a -13% annual free‑cash‑flow growth rate for the next decade—an unrealistic assumption given the current 11.7% revenue growth, meaning the market is already pricing in overly optimistic upside; any slowdown in enrollment or margin compression would expose this gap. A single analyst’s buy rating and a 52‑week low of $26.66 also signal limited analyst coverage, and a dip below the 52‑week low would confirm the valuation is overstretched.
Horizon. 1-3 yr $37.35 (structural (no analyst coverage)) — fundamentals + valuation re-rating. 5 yr $54.69 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $81.12 if current growth sustains into durable earnings power.
19. DECK — Deckers Outdoor Corporation · score 79.7
Footwear & Accessories · price $88.86 · 1Y $122.81 · 5Y $179.81 · 10Y $266.73
FCF $1.1b C+ · Rev +7.9% B · D/E 0.21 A- · P/E 12.6x A- · PEG 1.12 B+
Why now. The bull case hinges on HOKA’s premium performance‑footwear franchise accelerating compounding earnings as it captures affluent runners and hikers, a market where Deckers enjoys category leadership. The business is delivering 7.9% revenue growth YoY, a robust 18.4% profit margin, and an eye‑popping 44.1% ROE, all underpinned by the Bull Rankings model’s Quality pillar of 96 – the strongest of the three. Moreover, our reverse‑DCF shows the current price embeds a pessimistic –2% FCF growth assumption, far below the actual growth trajectory, leaving ample upside. The thesis rests on HOKA’s continued pricing power and margin expansion driving a high‑quality compounder.
Moat. Deckers’ moat derives from HOKA’s patented midsole technology and its entrenched presence in specialty running and trail‑shoe retailers, creating a cost‑to‑switch for athletes who value performance‑driven fit. This technical edge, combined with the UGG and Teva brands’ differentiated design pipelines, fuels pricing power that translates into the 44.1% ROE, far above the sector norm, and is not easily replicated by generic footwear makers.
Risk. The bear case centers on a potential slowdown in discretionary spend on premium outdoor footwear, which would blunt HOKA’s growth and compress margins; the stock already trades at a forward P/E of 12.6, modest but still assumes sustained 7.9% top‑line growth. A dip in consumer confidence could push the share toward its 52‑week low of $78.91, and a widening beta of 1.17 would amplify downside in a market pullback. Confirmation would come if quarterly revenue growth falls below 5% and the price slides below $80, eroding the quality premium.
Horizon. 1-3 yr $122.81 (analyst consensus (n=21)) — fundamentals + valuation re-rating. 5 yr $179.81 at ~15% CAGR — compounding case rests on the competitive position widening. 10 yr $266.73 if current growth sustains into durable earnings power.
20. GMED — Globus Medical, Inc. · score 79.2
Medical Devices · price $85.67 · 1Y $103.23 · 5Y $151.14 · 10Y $224.21
FCF $756m C+ · Rev +19.7% B+ · D/E 0.02 A- · P/E 21.9x B+ · PEG 1.49 B
Why now. Globus Medical is a high-conviction growth play, underpinned by robust demand for its specialized musculoskeletal solutions. Our model's 'Growth' pillar, scoring an exceptional 93/100 against sector peers, is validated by the company's impressive 19.7% FY YoY revenue growth. With a healthy $756m in TTM free cash flow and a remarkably low 0.02 debt-to-equity ratio, GMED possesses the financial strength to continue innovating and expanding its market share in spine products and orthopedic trauma solutions. The market's current pricing, implying only ~3%/yr FCF growth for 10 years, dramatically underestimates the compounding power of this medical device leader.
Moat. GMED's durable edge stems from the high switching costs inherent in specialized medical devices like its traditional fusion implants and motion preservation technologies. Surgeons and hospitals invest heavily in training and integration for specific systems, creating significant stickiness. The company's focus on developing and commercializing advanced healthcare solutions for musculoskeletal disorders, including complex biologic solutions, further strengthens its position by requiring extensive R&D and regulatory approvals, which are formidable barriers to entry for competitors.
Risk. The primary bear case centers on the market's skepticism regarding GMED's long-term free cash flow conversion and the competitive pressures within the medical device sector. Our model's weakest pillar, 'Quality' at 73/100, suggests potential concerns about operational efficiency or consistency relative to top-tier peers, despite strong growth. While revenue growth is robust, the current 21.9 P/E ratio could be vulnerable if the company struggles to translate its 19.7% top-line expansion into significantly higher FCF growth than the ~3% currently implied by the stock price. A sustained deceleration in revenue growth or margin contraction in its core spine product segments would confirm the bear thesis.
Horizon. 1-3 yr $103.23 (analyst consensus (n=13)) — fundamentals + valuation re-rating. 5 yr $151.14 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $224.21 if current growth sustains into durable earnings power.
21. META — Meta Platforms, Inc. · score 79.1
Internet Content & Information · price $545.83 · 1Y $754.14 · 5Y $1,104 · 10Y $1,638
FCF $41.0b A · Rev +27.7% A- · D/E 0.43 B+ · P/E 20.6x B · PEG 0.82 B+
Why now. Meta’s Family of Apps (FoA) is locked into a self‑reinforcing loop of user engagement and ad spend, driving 27.7% YoY revenue growth, a 29.8% profit margin and $41.0 billion of free cash flow. Our Bull Rankings model gives META a Quality‑Growth score of 79.1, with Growth as the strongest pillar, confirming that the business’s compounding engine is real. The thesis hinges on the FoA segment continuing to monetize its massive global user base at these rates, which will keep the 10‑year implied 29% FCF growth from the reverse‑DCF realistic.
Moat. The FoA segment’s network effects create a moat: every additional user makes the platform more valuable to advertisers, locking in high‑margin ad dollars that fuel a ROE of 26.1%. This pricing power, combined with deep integration of Facebook, Instagram and Messenger, gives Meta a cost‑efficient distribution channel that rivals can’t replicate quickly.
Risk. The price already embeds a 29% annual FCF growth assumption, far above the 27.7% revenue growth rate, and a P/E of 20.6 suggests limited downside cushion. A slowdown in ad spend or a misstep in Reality Labs could push the beta‑adjusted risk higher; a sustained miss on growth would validate the weak Value pillar (62) and could see the stock retreat toward its 52‑week low of $520.26.
Horizon. 1-3 yr $754.14 (analyst consensus (n=57)) — fundamentals + valuation re-rating. 5 yr $1,104 at ~15% CAGR — compounding case rests on the competitive position widening. 10 yr $1,638 if current growth sustains into durable earnings power.
22. CPAY — Corpay, Inc. · score 78.8
Software - Infrastructure · price $412.00 · 1Y $450.64 · 5Y $659.79 · 10Y $978.75
FCF $1.6b C+ · Rev +20.4% A- · D/E 2.75 D · P/E 25.0x B+ · PEG 0.93 B+
Why now. Corpay, Inc. stands out as a high-quality compounder, with our model's strongest pillar being Growth at 92/100. The company's diverse payment solutions across Corporate Payments, Vehicle Payments, and Lodging Payments are driving robust expansion, evidenced by a 20.4% FY YoY revenue growth and a strong 22.7% profit margin. Despite this impressive operational performance, the market appears to be underpricing its future potential: our reverse DCF analysis indicates today's price implies only ~3%/yr free-cash-flow growth sustained for 10 years, a stark contrast to its current revenue trajectory and a PEG ratio of 0.93. This suggests significant upside as CPAY continues to convert its growth into free cash flow.
Moat. CPAY's durable edge stems from the embedded nature of its payment solutions within critical business operations, creating high switching costs for its clients. Whether it's vehicle payment solutions for fuel, tolls, and fleet maintenance, or corporate payment solutions like AP modernization and cross-border payments, Corpay becomes an integral part of its customers' expense management infrastructure. This deep integration, coupled with recurring revenue streams from essential services, underpins the company's exceptional 32.2% Return on Equity, a testament to its pricing power and operational efficiency within these specialized payment ecosystems. Our model also signals "Durable high returns," reinforcing the strength of this competitive advantage.
Risk. The primary concern for Corpay, Inc. lies in its capital structure, which our model reflects in its weakest pillar, Value (60/100). Bears will point to the elevated debt-to-equity ratio of 2.75, which could amplify risks during economic downturns or periods of rising interest rates, potentially constraining future growth investments or share repurchases. While the company demonstrates strong profitability, this leverage introduces a vulnerability that could be exacerbated if the robust 20.4% revenue growth were to decelerate unexpectedly, making debt servicing a more significant burden. A sustained increase in interest expenses or a tightening of credit markets would confirm the bear case.
Horizon. 1-3 yr $450.64 (analyst consensus (n=14)) — fundamentals + valuation re-rating. 5 yr $659.79 at ~10% CAGR — compounding case rests on the competitive position widening. 10 yr $978.75 if current growth sustains into durable earnings power.
23. ACN — Accenture plc · score 78.4
Information Technology Services · price $181.35 · 1Y $179.11 · 5Y $262.23 · 10Y $389.00
FCF $12.6b A- · Rev +6.7% C+ · D/E 0.25 B · P/E 14.5x A- · PEG 1.33 B
Why now. Accenture’s AI‑driven cloud and intelligent platform services are the engine of its next growth wave, feeding a 6.7% YoY revenue increase and a robust 10.7% profit margin that fuels a free‑cash‑flow stream of $12.6B. The Bull Rankings model gives ACN a Quality‑growth score of 78.4, with Quality (89) as its strongest pillar, underscoring the firm’s high‑margin, repeatable delivery model. The only thing that matters is whether the AI‑cloud franchise can keep compounding faster than the reverse‑DCF implied -8% FCF growth, which it already outpaces by a wide margin.
Moat. Accenture’s global delivery network and deep integration expertise lock in multi‑year contracts for Fortune‑500 clients across finance, supply chain and HR, creating switching costs that protect its pricing power and drive an ROE of 24.4%. Its platform trust and safety services, combined with industry‑specific AI solutions, are hard for competitors to replicate quickly, cementing a durable moat around its high‑value consulting engagements.
Risk. The biggest headwind is the market’s expectation of continued high earnings growth, reflected in a forward P/E of 14.5 versus modest 6.7% revenue growth, a concern amplified by our model's weakest pillar being Growth (71). This suggests the price already embeds optimism that may be hard to sustain. A slowdown in AI‑cloud spend or a rise in the debt‑to‑equity ratio beyond the current 0.25 could pressure margins, and a beta of 1.07 means the stock is not immune to broader tech volatility. A miss on quarterly revenue growth would trigger a sell‑off, confirming the bear case.
Horizon. 1-3 yr $179.11 (analyst consensus (n=25)) — fundamentals + valuation re-rating. 5 yr $262.23 at ~8% CAGR — compounding case rests on the competitive position widening. 10 yr $389.00 if current growth sustains into durable earnings power.
24. BSX — Boston Scientific Corporation · score 78.3
Medical Devices · price $49.37 · 1Y $62.69 · 5Y $79.14 · 10Y $101.50
FCF $3.6b B · Rev +13.5% B+ · D/E 0.50 B · P/E 20.0x A- · PEG 0.75 A-
Why now. Medical Devices · market cap $71.5b. Down 55% from 52-week high of $109.50 — deep drawdown territory. Revenue growing +14%, comfortably above the S&P median. PEG 0.75 — paying under fair value for the growth rate. 29 sell-side analysts rate this a Buy with a mean 1-yr target of $62.69 (implying +27% upside).
Moat. Net margin 17% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 15% meets the long-run market sustainable threshold — solid but not differentiated; the durability comes from elsewhere. FCF converts 99% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Down 55% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up.
Horizon. 1-3 yr $62.69 (analyst consensus (n=29)) — multiple re-rating thesis requires a catalyst. 5 yr $79.14 at ~10% CAGR — dividend + buyback compounding. 10 yr $101.50 if the moat survives secular pressure.
25. VEEV — Veeva Systems Inc. · score 77.8
Health Information Services · price $250.53 · 1Y $251.43 · 5Y $368.12 · 10Y $546.08
FCF $1.7b C+ · Rev +16.2% B+ · D/E 0.01 A- · P/E 44.3x C · PEG 1.13 B+
Why now. Health Information Services · market cap $40.7b. 19% off the 52-week high of $310.50. Revenue growing +16%, comfortably above the S&P median. 28 sell-side analysts rate this a Buy with a mean 1-yr target of $251.43 (implying +0% upside).
Moat. Net margin 28% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. ROE 13% meets the long-run market sustainable threshold — solid but not differentiated; the durability comes from elsewhere. FCF converts 177% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Trailing P/E 44x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates. P/S 12.3x embeds aggressive forward growth — disappointing top-line guidance would compress the multiple hard.
Horizon. 1-3 yr $251.43 (analyst consensus (n=28)) — fundamentals + valuation re-rating. 5 yr $368.12 at ~8% CAGR — compounding case rests on the competitive position widening. 10 yr $546.08 if current growth sustains into durable earnings power.
26. WMG — Warner Music Group Corp. · score 77.2
Entertainment · price $27.10 · 1Y $36.88 · 5Y $46.56 · 10Y $59.72
FCF $836m C+ · Rev +12.9% B+ · D/E 4.53 D · P/E 21.7x B · PEG 0.49 A
Why now. Entertainment · market cap $14.2b. Down 23% from 52-week high of $35.42 — deep drawdown territory. Revenue growing +13%, comfortably above the S&P median. PEG 0.49 — paying under fair value for the growth rate. 17 sell-side analysts rate this a Buy with a mean 1-yr target of $36.88 (implying +36% upside).
Moat. ROE 79% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. FCF converts 124% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. D/E 4.53 is elevated — limits strategic flexibility and raises refinancing exposure if rates stay higher for longer.
Horizon. 1-3 yr $36.88 (analyst consensus (n=17)) — multiple re-rating thesis requires a catalyst. 5 yr $46.56 at ~11% CAGR — dividend + buyback compounding. 10 yr $59.72 if the moat survives secular pressure.
27. CCK — Crown Holdings, Inc. · score 75.4
Packaging & Containers · price $117.15 · 1Y $136.57 · 5Y $172.42 · 10Y $221.12
FCF $1.2b C+ · Rev +10.3% B · D/E 1.86 C+ · P/E 16.9x B+ · PEG 0.64 A-
Why now. Packaging & Containers · market cap $12.7b. 5% off the 52-week high of $122.91. Revenue growing +10%, comfortably above the S&P median. PEG 0.64 — paying under fair value for the growth rate. 14 sell-side analysts publish a mean 1-yr target of $136.57 (implying +17% upside).
Moat. ROE 27% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. FCF converts 153% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Value re-rating depends on a catalyst. Without one — analyst day, divestiture, margin recovery, capital return — the stock can stay cheap on these multiples for years.
Horizon. 1-3 yr $136.57 (analyst consensus (n=14)) — multiple re-rating thesis requires a catalyst. 5 yr $172.42 at ~8% CAGR — dividend + buyback compounding. 10 yr $221.12 if the moat survives secular pressure.
28. EME — EMCOR Group, Inc. · score 75.3
Engineering & Construction · price $787.39 · 1Y $1,033 · 5Y $1,304 · 10Y $1,673
FCF $1.2b C+ · Rev +18.9% B+ · D/E 0.13 A- · P/E 24.5x B+ · PEG 0.40 A
Why now. Engineering & Construction · market cap $34.7b. 17% off the 52-week high of $951.96. Revenue growing +19%, comfortably above the S&P median. PEG 0.40 — paying under fair value for the growth rate. 7 sell-side analysts rate this a Buy with a mean 1-yr target of $1,033 (implying +31% upside).
Moat. ROE 35% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which.
Risk. Value re-rating depends on a catalyst. Without one — analyst day, divestiture, margin recovery, capital return — the stock can stay cheap on these multiples for years.
Horizon. 1-3 yr $1,033 (analyst consensus (n=7)) — multiple re-rating thesis requires a catalyst. 5 yr $1,304 at ~11% CAGR — dividend + buyback compounding. 10 yr $1,673 if the moat survives secular pressure.
29. CF — CF Industries Holdings, Inc. · score 74.5
Agricultural Inputs · price $125.70 · 1Y $125.77 · 5Y $158.79 · 10Y $203.64
FCF $1.9b C+ · Rev +20.0% A- · D/E 0.41 B · P/E 9.3x A · PEG 0.40 A
Why now. Agricultural Inputs · market cap $19.0b. 11% off the 52-week high of $141.96. Revenue growing +20%, comfortably above the S&P median. PEG 0.40 — paying under fair value for the growth rate. 19 sell-side analysts rate this a Hold with a mean 1-yr target of $125.77 (implying +0% upside).
Moat. Net margin 32% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. ROE 43% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which.
Risk. Value re-rating depends on a catalyst. Without one — analyst day, divestiture, margin recovery, capital return — the stock can stay cheap on these multiples for years.
Horizon. 1-3 yr $125.77 (analyst consensus (n=19)) — multiple re-rating thesis requires a catalyst. 5 yr $158.79 at ~5% CAGR — dividend + buyback compounding. 10 yr $203.64 if the moat survives secular pressure.
30. YUMC — Yum China Holdings, Inc. · score 74.5
Restaurants · price $48.88 · 1Y $62.05 · 5Y $90.85 · 10Y $134.77
FCF $940m C+ · Rev +8.8% B · D/E 0.38 A- · P/E 17.9x B+ · PEG 1.19 B+
Why now. Restaurants · market cap $16.7b. 16% off the 52-week high of $58.39. 21 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $62.05 (implying +27% upside).
Moat. ROE 18% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 96% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Mature compounder — the risk is paying up for quality at a moment when growth is decelerating. Watch for sequential revenue + margin trends; the inflection from "compounder" to "ex-compounder" is hard to spot until the multiple already started compressing.
Horizon. 1-3 yr $62.05 (analyst consensus (n=21)) — fundamentals + valuation re-rating. 5 yr $90.85 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $134.77 if current growth sustains into durable earnings power.
Methodology footnote
Every pick on this list comes out of the same quality-growth model — one 0–100 score blending quality, growth, and value — applied to every US-listed common stock with a market cap above $1B. Each pick's score breakdown is auditable from the home page — click the ticker on the rankings page to see exactly which grades produced the number. Not investment advice. See terms for full disclosures.